Brief in vitro IL-12 conditioning of CD8 + T Cells for anticancer adoptive T cell therapy
ML Salem, S Salman, IO Barnawi - Cancer Immunology, Immunotherapy, 2021 - Springer
Cancer immunotherapy represents a potential treatment approach through non-specific and
specific enhancement of the immune responses. Adoptive cell therapy (ACT) is a potential …
specific enhancement of the immune responses. Adoptive cell therapy (ACT) is a potential …
Interleukin-12 enhances the function and anti-tumor activity in murine and human CD8+ T cells
MP Rubinstein, EW Su, S Suriano, CA Cloud… - Cancer Immunology …, 2015 - Springer
Mouse CD8+ T cells conditioned with interleukin (IL)-12 ex vivo mediate the potent
regression of established melanoma when transferred into lymphodepleted mice. However …
regression of established melanoma when transferred into lymphodepleted mice. However …
Enhanced sensitivity to IL-2 signaling regulates the clinical responsiveness of IL-12–primed CD8+ T cells in a melanoma model
The optimal expansion, trafficking, and function of adoptively transferred CD8+ T cells are
parameters that currently limit the effectiveness of antitumor immunity to established tumors …
parameters that currently limit the effectiveness of antitumor immunity to established tumors …
IL-12 enhances the generation of tumour antigen-specific Th1 CD4 T cells during ex vivo expansion
KL Knutson, ML Disis - Clinical & Experimental Immunology, 2004 - academic.oup.com
SUMMARY CD4+ T cells are essential for the immune response against cancer. Vaccination
against cancer will likely only be effective at preventing growth of micrometastatic disease …
against cancer will likely only be effective at preventing growth of micrometastatic disease …
Ex vivo interleukin-12-priming during CD8+ T cell activation dramatically improves adoptive T cell transfer antitumor efficacy in a lymphodepleted host
MP Rubinstein, CA Cloud, TE Garrett, CJ Moore… - Journal of the American …, 2012 - Elsevier
BACKGROUND: Clinical application of adoptive T cell therapy has been hindered by an
inability to generate adequate numbers of nontolerized, functionally active, tumor-specific T …
inability to generate adequate numbers of nontolerized, functionally active, tumor-specific T …
Ex vivo conditioning with IL-12 protects tumor-infiltrating CD8+ T cells from negative regulation by local IFN-γ
L Lin, P Rayman, PG Pavicic, C Tannenbaum… - Cancer Immunology …, 2019 - Springer
Optimal ex vivo expansion protocols for adoptive cell therapy (ACT) must yield T cells able to
effectively home to tumors and survive the inhospitable conditions of the tumor …
effectively home to tumors and survive the inhospitable conditions of the tumor …
Generating potent Th1/Tc1 T cell adoptive immunotherapy doses using human IL-12: harnessing the immunomodulatory potential of IL-12 without the in vivo …
PCR Emtage, D Clarke… - Journal of …, 2003 - journals.lww.com
Abstract Interleukin (IL)-12 is a cytokine originally identified from medium conditioned by an
Epstein-Barr virus transformed cell line. IL-12 has been shown to increase IFN-γ secretion …
Epstein-Barr virus transformed cell line. IL-12 has been shown to increase IFN-γ secretion …
[HTML][HTML] Adoptive immunotherapy via CD4+ versus CD8+ T cells
V Phan-Lai - Biomedical Research and Therapy, 2016 - Springer
The goal of cancer immunotherapy is to induce specific and durable antitumor immunity.
Adoptive T cell therapy (ACT) has garnered wide interest, particularly in regard to strategies …
Adoptive T cell therapy (ACT) has garnered wide interest, particularly in regard to strategies …
Interleukin-12 requires initial CD80-mediated T-cell activation to support immune responses toward human breast and ovarian carcinoma
B Gückel, GC Meyer, W Rudy, R Batrla… - Cancer Gene …, 1999 - nature.com
One possible reason for the poor immunogenicity of tumors is the induction of peripheral
tolerance by tumor cells that fail to deliver costimulatory signals. Furthermore, T cells …
tolerance by tumor cells that fail to deliver costimulatory signals. Furthermore, T cells …
Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts
SP Kerkar, P Muranski, A Kaiser, A Boni… - Cancer research, 2010 - AACR
T-cell–based immunotherapies can be effective in the treatment of large vascularized
tumors, but they rely on adoptive transfer of substantial numbers (∼ 20 million) of tumor …
tumors, but they rely on adoptive transfer of substantial numbers (∼ 20 million) of tumor …